FDA OKs hot-flash drug from Pfizer, Ligand

10/4/2013 | Bloomberg

The FDA has granted Pfizer and Ligand Pharmaceuticals approval for their osteoporosis and hot-flash treatment Duavee. The medication is to be used in postmenopausal women who haven't had a hysterectomy and who suffer moderate to severe hot flashes. The drug is also indicated for prevention of post-menopausal osteoporosis.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA